Ultragenyx Pharmaceutical (RARE) reported a Q3 net loss late Tuesday of $1.40 per diluted share, narrowing from a loss of $2.23 a year earlier.
Analysts polled by Capital IQ expected a loss of $1.48.
Revenue in the three months ended Sept. 30 rose to $139.5 million from $98.1 million a year earlier. Analysts surveyed by Capital IQ expected $135.3 million.
The company expects 2024 revenue of $530 million to $550 million. Analysts polled by Capital IQ expect $537 million.
Shares of the company fell 5.8% in recent after-hours activity.
Price: 49.17, Change: -3.01, Percent Change: -5.77
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.